Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 13;69(2):e0138724.
doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.

How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?

Kimberly C Claeys  1 , Patricia J Simner  2   3 , Tsigereda Tekle  3 , Anthony D Harris  4 , Emily Jacobs  3 , Sara E Cosgrove  2 , Pranita D Tamma  5
Affiliations

How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?

Kimberly C Claeys et al. Antimicrob Agents Chemother. .

Abstract

The reliability of ceftriaxone for inferring susceptibility to higher-generation oral cephalosporins is unknown. Overall, ceftriaxone susceptibility predicted susceptibility to cefuroxime (89%), cefdinir (86%), cefpodoxime (90%), and cefixime (94%) based on disk diffusion results for 409 consecutive Enterobacterales bloodstream isolates from unique patients. Susceptibility percentages to the four oral cephalosporins ranged from 92% to 99% when limited to Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis isolates susceptible to ceftriaxone.

Keywords: cefdinir; cefixime; cefpodoxime; ceftriaxone; cefuroxime.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Tingsgård S, Bastrup Israelsen S, Jørgensen HL, Østergaard C, Benfield T. 2024. Early switch from intravenous to oral antibiotics for patients with uncomplicated Gram-negative bacteremia. JAMA Netw Open 7:e2352314. doi:10.1001/jamanetworkopen.2023.52314 - DOI - PMC - PubMed
    1. Engers DW, Tamma PD, Fiawoo S, Fong K, Jariwala R, Jenkins TC, Kendall RE, Lee JH, McCreary EK, Patel PK, Shihadeh KC, Slish J, Van Schooneveld TC, Malani AN. 2024. Transition to oral antibiotic therapy for hospitalized adults with Gram-negative bloodstream infections. JAMA Netw Open 7:e2349864. doi:10.1001/jamanetworkopen.2023.49864 - DOI - PMC - PubMed
    1. Tamma PD, Conley AT, Cosgrove SE, Harris AD, Lautenbach E, Amoah J, Avdic E, Tolomeo P, Wise J, Subudhi S, Han JH, Antibacterial Resistance Leadership Group . 2019. Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with enterobacteriaceae bacteremia. JAMA Intern Med 179:316–323. doi:10.1001/jamainternmed.2018.6226 - DOI - PMC - PubMed
    1. Thaden JT, Tamma PD, Doi Y, Daneman N, Antibacterial Resistance Leadership G. 2021. Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. Int J Antimicrob Agents 58:106451. doi:10.1016/j.ijantimicag.2021.106451 - DOI - PMC - PubMed
    1. Kutob LF, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. 2016. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections. Int J Antimicrob Agents 48:498–503. doi:10.1016/j.ijantimicag.2016.07.013 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources